Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-9591 in EGFR-mutated NSCLC with brain metastases
CTR20212878Phase 2Completed
- Sponsor
- TYK Medicines
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Started Nov 2021; status: completed.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212878.